Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.59 |
| ▸ | TPH1 | P17752 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GRB2 | P62993 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23097542 | 1.00 | SLC7A5 (0.59) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL17655684 | 0.86 | SLC7A5 (0.62) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL18570637 | 0.85 | TAAR1 (0.52) | SLC6A3 | |
| SCHEMBL12142607 | 0.83 | SLC7A5 (0.62) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL826649 | 0.83 | SLC7A5 (0.62) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL6777440 | 0.82 | SLC7A5 (0.67) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL93538 | 0.82 | SLC7A5 (0.67) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL93537 | 0.82 | SLC7A5 (0.67) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL20275205 | 0.82 | TPH1 (0.42) | SLC7A5TPH1PTGS1ALPIPKM | |
| SCHEMBL2310526 | 0.82 | SLC7A5 (0.83) | SLC7A5TPH1PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344626-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3336103-B1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200299403-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200283543-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10669347-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-10501558-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| EP-3505534-A1 | ANTIBODIES COMPRISING SITESPECIFIC NONNATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-2859017-B1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180036425-A1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180036425-A1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9738724-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9732161-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732161-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3135690-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | Sutro Biopharma, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2863955-B1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2016-11-23 | — | — | EP | disclosed |
| WO-2015006555-A2 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | SUTRO BIOPHARMA, INC. | 2014-02-20 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051836-A1 | Modified Fc Proteins Comprising Site-Specific Non-Natural Amino Acid Residues, Conjugates of the Same, Methods of Their Preparation and Methods of Their Use | FCGR2A, FCGR3B, FCGR1A | SLC7A5 888/4885TPH1 4663/4885PTGS1 3984/4885 |
| US-10501558-B2 | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use | FCGR2A, FCGR3B, FCGR1A | SLC7A5 888/4885TPH1 4663/4885PTGS1 3984/4885 |
| US-10669347-B2 | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, LNPEP, ANPEP | SLC7A5 310/4885TPH1 4404/4885PTGS1 4729/4885 |
| US-20200299403-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, LNPEP, ANPEP | SLC7A5 310/4885TPH1 4404/4885PTGS1 4729/4885 |
| US-20180036425-A1 | ANTIBODIES COMPRISING MULTIPLE SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, VSIG8, LNPEP | SLC7A5 502/4885TPH1 4676/4885PTGS1 4729/4885 |
| US-20200283543-A1 | MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | FCGR2A, FCGR3B, FCGR1A | SLC7A5 888/4885TPH1 4663/4885PTGS1 3984/4885 |
| US-20140046030-A1 | ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USE | DNPEP, LNPEP, ANPEP | SLC7A5 310/4885TPH1 4404/4885PTGS1 4729/4885 |
| US-11344626-B2 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use | DNPEP, VSIG8, LNPEP | SLC7A5 502/4885TPH1 4676/4885PTGS1 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.